Literature DB >> 29548911

Involvement of GABAergic, BDNF and Nox-2 mechanisms in the prevention and reversal of ketamine-induced schizophrenia-like behavior by morin in mice.

Benneth Ben-Azu1, Adegbuyi Oladele Aderibigbe2, Abayomi Mayowa Ajayi2, Aya-Ebi Okubo Eneni2, Solomon Umukoro2, Ezekiel O Iwalewa2.   

Abstract

GABAergic (Gamma-aminobutyric acid) and neurotrophic derangements have important implication in schizophrenia, a neuropsychiatric disease. Previous studies have shown that nicotinamide adenine dinucleotide phosphate oxidase (NADPH-oxidase) alters GABAergic and neurotrophic activities via inflammatory and oxidative pathways. Thus, it has been proposed that agents with anti-oxidant and anti-inflammatory properties might be beneficial for the treatment of the disease. Morin is neuroactive bioflavonoid compound, which has been reported to demonstrate antipsychotic and anti-oxidant/anti-inflammatory activities. In this study, we further evaluated its effects on the brain markers of GABAergic, neurotrophic and oxidative alterations in the preventive and reversal of schizophrenia-like behavior induced by ketamine (KET). In the prevention protocol, adult mice were treated intraperitoneally with morin (100 mg/kg/day), haloperidol (1 mg/kg/day), risperidone (0.5 mg/kg/day), or saline (10 mL/kg/day) for 14 consecutive days. In addition, the animals were administered KET (20 mg/kg/day) from the 8th to the 14th day. In the reversal protocol, the animals received KET or saline for 14 days. From 8th to 14th days mice were additionally treated with morin, haloperidol, risperidone or saline. Schizophrenic-like behaviors consisting of positive (stereotypy test), negative (behavioral despair in forced swim test) and cognitive (novel-object recognition test) symptoms were evaluated. Afterwards, brain levels of biomarkers of GABAergic (Glutamic acid decarboxylase-67, GAD67), neurotrophic (Brain-derived neurotrophic factor, BDNF) and oxidative [NADPH-oxidase, superoxide dismutase, (SOD) and catalase (CAT)] alterations were determined in the striatum, prefrontal cortex (PFC) and hippocampus, respectively. Morin significantly (p < 0.05) prevented and reversed KET-induced increased stereotypy, behavioral despair and deficit in cognitive functions when compared with KET-treated mice respectively. Also, morin and risperidone but not haloperidol, significantly (p < 0.05) prevented and reversed the decreases in expressions of GAD67 and BDNF immunoreactivity in the striatum, PFC and hippocampus caused by KET. Moreover, morin and risperidone significantly (p < 0.05) decreased regional brain expressions of NADPH-oxidase immunopositive cells and increased endogenous anti-oxidant enzymes (SOD and CAT) in the striatum, PFC and hippocampus relative to KET controls respectively. Taken together, these findings further suggest that the antipsychotic-like activity of morin may be mediated via mechanisms related to enhancement of GABAergic neurotransmission and neurotrophic factor, and suppression of NADPH-oxidase induced oxidative damage in mice.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Antioxidants; Antipsychotics; GABA; Neurotrophins; Schizophrenia

Mesh:

Substances:

Year:  2018        PMID: 29548911     DOI: 10.1016/j.brainresbull.2018.03.006

Source DB:  PubMed          Journal:  Brain Res Bull        ISSN: 0361-9230            Impact factor:   4.077


  6 in total

1.  Morin Attenuates Neurochemical Changes and Increased Oxidative/Nitrergic Stress in Brains of Mice Exposed to Ketamine: Prevention and Reversal of Schizophrenia-Like Symptoms.

Authors:  Benneth Ben-Azu; Adegbuyi Oladele Aderibigbe; Aya-Ebi Okubo Eneni; Abayomi Mayowa Ajayi; Solomon Umukoro; Ezekiel O Iwalewa
Journal:  Neurochem Res       Date:  2018-06-28       Impact factor: 3.996

2.  Molecular mechanisms involved in the prevention and reversal of ketamine-induced schizophrenia-like behavior by rutin: the role of glutamic acid decarboxylase isoform-67, cholinergic, Nox-2-oxidative stress pathways in mice.

Authors:  Tolulope Olabode Oshodi; Benneth Ben-Azu; Ismail O Ishola; Abayomi Mayowa Ajayi; Osagie Emokpae; Solomon Umukoro
Journal:  Mol Biol Rep       Date:  2021-04-03       Impact factor: 2.316

3.  Morin hydrate attenuates chronic stress-induced memory impairment and degeneration of hippocampal subfields in mice: The role of oxidative, nitrergic and neuroinflammatory pathways.

Authors:  Akinluyi Elizabeth; Aderibigbe Adegbuyi; Adeoluwa Olusegun; Ben-Azu Benneth; Eduviere Anthony; Ajayi Abayomi; Umukoro Solomon
Journal:  Metab Brain Dis       Date:  2020-07-11       Impact factor: 3.584

4.  Involvement of anti-inflammatory, antioxidant, and BDNF up-regulating properties in the antipsychotic-like effect of the essential oil of Alpinia zerumbet in mice: a comparative study with olanzapine.

Authors:  Fernanda Yvelize Ramos de Araújo; Adriano José Maia Chaves Filho; Adriana Mary Nunes; Gersilene Valente de Oliveira; Patrícia Xavier Lima Gomes; Germana Silva Vasconcelos; Jaqueline Carletti; Manoel Odorico de Moraes; Maria Elisabete de Moraes; Silvânia Maria Mendes Vasconcelos; Francisca Cléa Florenço de Sousa; David Freitas de Lucena; Danielle S Macedo
Journal:  Metab Brain Dis       Date:  2021-09-07       Impact factor: 3.584

5.  Taurine, an essential β-amino acid insulates against ketamine-induced experimental psychosis by enhancement of cholinergic neurotransmission, inhibition of oxidative/nitrergic imbalances, and suppression of COX-2/iNOS immunoreactions in mice.

Authors:  Benneth Ben-Azu; Olusegun G Adebayo; Thiophilus Aghogho Jarikre; Mega O Oyovwi; Kesiena Emmanuel Edje; Itivere Adrian Omogbiya; Anthony T Eduviere; Emuesiri Goodies Moke; Bienose S Chijioke; Onyebuchi S Odili; Osemudiame P Omondiabge; Aghogho Oyovbaire; Daniel T Esuku; Esther O Ozah; Kelvin Japhet
Journal:  Metab Brain Dis       Date:  2022-09-03       Impact factor: 3.655

Review 6.  Advantages and Limitations of Animal Schizophrenia Models.

Authors:  Magdalena Białoń; Agnieszka Wąsik
Journal:  Int J Mol Sci       Date:  2022-05-25       Impact factor: 6.208

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.